Skip to main content
Premium Trial:

Request an Annual Quote

Dana-Farber, Broad Team Uses shRNA Screen to ID Ovarian Cancer-Related Gene

Premium

Researchers from the Dana-Farber Cancer Institute, in collaboration with the Broad Institute, published research this week showing that a genome-scale shRNA study of more than 100 cancer cell lines revealed previously unknown lineage-specific dependencies in ovarian cancer.

The findings appeared in the Proceedings of the National Academy of Sciences.

The researchers used a pool of more than 54,000 shRNAs contained in a library developed by the Broad's RNAi Consortium (GSN 8/5/2010) to study the cell lines, which included 25 ovarian cancer tumors. The work revealed 54 genes that are essential for ovarian cancer proliferation and viability.

One gene in particular, PAX8, was found to be amplified in 16 percent of high-grade serious ovarian cancers, and expressed at higher levels in ovarian tumors, according to the paper.

“Suppression of PAX8 selectively induces apoptotic cell death of ovarian cancer cells,” the study's authors wrote.

In addition to identifying PAX8 as an ovarian lineage-specific dependency, the findings demonstrate that “the integration of genome-scale functional and structural studies provides an efficient path to identify dependencies of specific cancer types on particular genes and pathways,” the authors added.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.